{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-006685","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2025-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.288906+00:00","generated_at":"2026-05-25T03:44:33.315138+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"confidence":"high","headline":"Nasdaq grants Avenue Therapeutics continued listing exception; AnnJi seeks to terminate AJ201 license","bullets":["Nasdaq Panel granted continued listing subject to: public disclosure by Mar 14, fundraising update by Mar 14, AJ201 trial results by Apr 15.","AnnJi sent termination notice alleging material breaches of AJ201 license; Avenue believes claims are meritless and will contest.","Avenue filed emergency arbitration to block AnnJi from unblinding clinical data in a way that would exhaust irreplaceable samples.","Company must still regain compliance with stockholders' equity requirement; no assurance of success."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-006685","json":"https://secwatch.observer/filing/0001437749-25-006685.json","markdown":"https://secwatch.observer/filing/0001437749-25-006685.md","text":"https://secwatch.observer/filing/0001437749-25-006685.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000143774925006685/0001437749-25-006685-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000143774925006685/atxi20250307_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T03:44:33.315138+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}